Navigation Links
Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray
Date:3/16/2011

CRANFORD, N.J., March 16, 2011 /PRNewswire/ -- Coronary artery disease (CAD), also known as coronary heart disease, is the most common type of heart disease, currently affecting about 17 million Americans(1). Most of these people suffer from a common symptom of CAD known as angina pectoris. For over 100 years, physicians have treated acute angina with nitrates, the most common form being nitroglycerin(2). Considered the gold standard in treating acute angina, nitroglycerin tablets have had problems with diminished stability and potency once dispensed(3-5). In recent years, nitroglycerin sprays were introduced and have alleviated much of the potency and stability concerns associated with the storage of tablets. Studies have shown that nitroglycerin sprays are capable of providing a more rapid form of symptom relief in most angina patients(6).

NitroMist® (Nitroglycerin Lingual Aerosol 400 mcg) is indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. It provides nitroglycerin in a rapidly absorbed, mentholated spray formulation, specifically designed for use on or under the tongue. NitroMist is available in a fully sealed aerosol delivery system, providing a shelf life of 36 months. NitroMist contains no ethyl alcohol.

Nitroglycerin sprays are proven to relieve the symptoms of angina significantly faster than tablets in most patients(6).

Wayne Anderson, Akrimax' President and CEO stated, "Akrimax is committed to providing health care providers and their patients with therapies that can make an important difference in the lives of patients. We believe NitroMist is an excellent example of this. NitroMist is the second new product that Akrimax has brought to market in the past year. Akrimax also has expanded its sales force by a third in order to educate health care providers about NitroMist and its other promoted brands, Tirosint and Inderal LA." Once primed, NitroMist's unique aerosol delivery system ensures consistent delivery with a propellant-driven, metered dose.*

Indications and Usage: NitroMist® is a nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.

Important Safety Information: NitroMist® should not be used in patients who are using phosphodiesterase type 5 inhibitors, such as those used for the treatment of erectile dysfunction, which have been shown to potentiate the hypotensive effects of organic nitrates. NitroMist should not be used in patients with severe anemia, in patients with increased intracranial pressure, and in patients with a history of hypersensitivity to this or other nitrates or nitrites. Skin reactions consistent with hypersensitivity have been observed with organic nitrates. NitroMist should be used with caution if patients have low systolic blood pressure, are undergoing diuretic therapy, or are undergoing tissue-type plasminogen activator therapy.

Co-administration of aspirin and nitroglycerin has been reported to increase nitroglycerin levels and intravenous nitroglycerin reduces the anticoagulant effect of heparin, so activated partial thromboplastin times should be monitored. Oral administration of nitroglycerin increases bioavailability of ergotamine, so concomitant use of ergotamine and related drugs should be avoided.

Excessive use may lead to the development of tolerance.

Severe hypotension, particularly with upright posture, may occur even with small doses of nitroglycerin. Hypotension induced by nitroglycerin may be accompanied by paradoxical bradycardia and increased angina pectoris. The benefits of NitroMist in patients with acute myocardial infarction or congestive heart failure have not been established. Nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy.

Nitroglycerin produces dose-related headaches, which may be severe. Tolerance to headaches occurs. The most common adverse reactions are headache, flushing, hypotension and syncope.

[Web version]

Click here for full Prescribing Information

[Email version]

Please see attached full Prescribing Information

*Priming NitroMist: After receiving a new prescription or refill, patients should remove the plastic cap, place forefinger on actuator button, and press 10 times. NitroMist is now primed for 6 weeks and ready to use. If not used for more than 6 weeks, the NitroMist bottle can be adequately reprimed with 2 sprays.

NitroMist is a registered trademark of Novadel Pharma, Inc., used by permission.

For more information about NitroMist please visit www.nitromist.com

About AkrimaxAkrimax Pharmaceuticals, LLC is a privately held, fully integrated next-generation specialty pharmaceutical company that acquires, markets, and develops products to address disease states related to cardiovascular, metabolic and endocrine diseases. Based in Cranford, NJ, Akrimax pursues unsurpassed quality in the development, production, manufacturing, distribution, and commercialization of a full range of top-quality pharmaceutical products.

For more information on NitroMist or other Akrimax products, please contact

Jim Misner or Aleen Hosdaghian of Akrimax Pharmaceuticals, LLC, 908.372.0500.

To learn more about Akrimax, please visit www.akrimax.com

References: 1. Heart disease and stroke statistics—2010 update. American Heart Association. 2010: pp1-36. 2. Coronary artery disease. http://adam.about.com/reports/Coronary-artery-disease.htm. Updated 5/15/2009. Accessed 2/22/2011. 3. O'Hanrahan M, McGarry K, Kelly JG, et al. Diminished activity of glyceryl trinitrate. Br Med J. 1982;284(6323):1183-1184. 4. Davis's Drug Guide.com. http://www.drugguide.com/ddo/ub/view/Davis-Drug-Guide/51548/all/nitroglycerin?q=nitroglycerin. Published 2010. Accessed June 21, 2010. 5. Tallett ER. Stability of glyceryl trinitrate tablets (letter). Br Med J. 1982;284:1403. 6. Vandenburg MJ, Wight, LJ, Griffiths GK, et al. Sublingual nitroglycerin or spray in the treatment of angina. Br J Clin Pract. 1986;40(12):524-527.Aleen HosdaghianAkrimax Pharmaceuticals, LLC908-372-1223ahosdaghian@akrimax.com
'/>"/>

SOURCE Akrimax Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... AVIV, Israel , March 27, 2017 ... on oncology and immunology, announced today that AGI-134, an immunotherapy ... announced acquisition of Agalimmune Ltd., will be featured at the ... in Washington, DC to be ... ...
(Date:3/27/2017)... March 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), ... address serious pulmonary diseases, today announced that it has added ... fibrosis and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the ... Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017  BERG, a ... data-driven, biological research approach, today announced that ... the discovery of new data using a ... brown fat metabolism. Joslin Diabetes Center led ... Biology® platform for analysis of samples.  The ...
Breaking Medicine Technology:
(Date:3/28/2017)... ORANGE, Calif. (PRWEB) , ... March 28, 2017 ... ... of its leading physicians, Paul Yost, will begin serving as new board chair ... earlier this month. Yost will serve the remainder of soon-to-be former chair Mark ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing effort ... has recently developed and published an informational resource that addresses frequently asked questions. ... common inquiries the site’s team of third party administrator (TPA) contributors regularly receives ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
(Date:3/28/2017)... ... ... common and unwelcomed occurrence in people of all ages, genders and ethnicities. Dermatologist Dr. Sonoa ... dealing with excess skin oil. “Oily skin is a challenge to many of my patients. ... oily shine while keeping the skin fresh and clean,” says Dr. Au. , What causes ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have ... sleep apnea treatment, with or without a referral. Sleep apnea is often left untreated ... daytime sleepiness, morning headaches and chronic snoring. , Dr. Braasch seeks to raise ...
Breaking Medicine News(10 mins):